Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.

PubWeight™: 0.94‹?›

🔗 View Article (PMID 23149919)

Published in Cancer Res on November 13, 2012

Authors

Maria C Ochoa1, Jessica Fioravanti, Inmaculada Rodriguez, Sandra Hervas-Stubbs, Arantza Azpilikueta, Guillermo Mazzolini, Alfonso Gúrpide, Jesus Prieto, Julian Pardo, Pedro Berraondo, Ignacio Melero

Author Affiliations

1: Center for Applied Medical Research, University of Navarra, Pamplona, Spain.

Articles citing this

Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. Immunol Cell Biol (2017) 1.05

Common gamma chain cytokines in combinatorial immune strategies against cancer. Immunol Lett (2015) 0.91

IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy. Cancer Res (2015) 0.81

IL-15 suppresses colitis-associated colon carcinogenesis by inducing antitumor immunity. Oncoimmunology (2015) 0.77

Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics. Cholesterol (2015) 0.77

A folate receptor-targeted lipoplex delivering interleukin-15 gene for colon cancer immunotherapy. Oncotarget (2016) 0.77

Identification of IFN-γ-producing T cells as the main mediators of the side effects associated to mouse interleukin-15 sustained exposure. Oncotarget (2016) 0.75

Exceptional antineoplastic activity of a dendritic-cell-targeted vaccine loaded with a Listeria peptide proposed against metastatic melanoma. Oncotarget (2016) 0.75

High-density lipoproteins delivering interleukin-15. Oncoimmunology (2013) 0.75

Routing cancer immunology and immunotherapy from the lab to the clinic 4-5 th March 2014, Center for Applied Medical Research and University Clinic, Pamplona, Spain. J Transl Med (2014) 0.75

The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy. Front Immunol (2017) 0.75

Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent. Cytokine Growth Factor Rev (2017) 0.75

Articles by these authors

Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32

Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut (2013) 3.08

Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst (2006) 2.69

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63

Human and mouse granzyme A induce a proinflammatory cytokine response. Immunity (2008) 2.57

Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32

Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology (2010) 2.18

Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00

The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov (2012) 1.95

Direct effects of type I interferons on cells of the immune system. Clin Cancer Res (2011) 1.91

A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. Gastroenterology (2003) 1.90

Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology (2005) 1.75

Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res (2005) 1.74

Gliotoxin is a virulence factor of Aspergillus fumigatus: gliP deletion attenuates virulence in mice immunosuppressed with hydrocortisone. Eukaryot Cell (2007) 1.69

Safety and liver transduction efficacy of rAAV5-cohPBGD in nonhuman primates: a potential therapy for acute intermittent porphyria. Hum Gene Ther (2013) 1.62

CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61

Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2006) 1.61

Dysregulation of interferon regulatory factors impairs the expression of immunostimulatory molecules in hepatitis C virus genotype 1-infected hepatocytes. Gut (2013) 1.50

Role of laeA in the Regulation of alb1, gliP, Conidial Morphology, and Virulence in Aspergillus fumigatus. Eukaryot Cell (2007) 1.41

Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribution in mice of both genders. Hum Gene Ther (2009) 1.37

Blockade of Wnt signaling inhibits angiogenesis and tumor growth in hepatocellular carcinoma. Cancer Res (2009) 1.33

Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol (2004) 1.25

SimB16: modeling induced immune system response against B16-melanoma. PLoS One (2011) 1.25

Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res (2008) 1.24

The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol (2005) 1.23

Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res (2011) 1.23

IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol (2008) 1.22

Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res (2011) 1.22

Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology (2013) 1.21

Acid sphingomyelinase is a key regulator of cytotoxic granule secretion by primary T lymphocytes. Nat Immunol (2009) 1.20

Genetic basis for clinical response to CTLA-4 blockade. N Engl J Med (2015) 1.18

Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol (2010) 1.17

In vitro and in vivo comparative study of chimeric liver-specific promoters. Mol Ther (2003) 1.17

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother (2010) 1.15

Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. Hepatology (2011) 1.14

Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res (2006) 1.14

N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB. Proc Natl Acad Sci U S A (2012) 1.14

Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol (2004) 1.13

Gene therapy of cancer based on interleukin 12. Curr Gene Ther (2005) 1.13

Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol (2003) 1.13

Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice. Glycobiology (2011) 1.11

Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer. Gastroenterology (2004) 1.09

In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur J Immunol (2009) 1.09

Cholangiocyte anion exchange and biliary bicarbonate excretion. World J Gastroenterol (2006) 1.08

Suppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factor. Mol Ther (2003) 1.06

Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice. Gut (2010) 1.06

Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. J Hepatol (2007) 1.06

In utero gene therapy: current challenges and perspectives. Mol Ther (2005) 1.05

Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res (2013) 1.05

Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes. Oncologist (2011) 1.04

Gene therapy of cancer with interleukin-12. Curr Pharm Des (2003) 1.04

Cardiotrophin-1 is an essential factor in the natural defense of the liver against apoptosis. Hepatology (2007) 1.04

Hepatocellular carcinoma cells and their fibrotic microenvironment modulate bone marrow-derived mesenchymal stromal cell migration in vitro and in vivo. Mol Pharm (2011) 1.04

Development of a liver-specific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancer. Mol Ther (2011) 1.03

Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. Mol Ther (2009) 1.03

A network analysis of the human T-cell activation gene network identifies JAGGED1 as a therapeutic target for autoimmune diseases. PLoS One (2007) 1.03

Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer (2005) 1.01

Bone-marrow-derived cell differentiation into microglia: a study in a progressive mouse model of Parkinson's disease. Neurobiol Dis (2007) 1.01

Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties. Hepatology (2011) 1.00

Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. Int J Cancer (2004) 1.00

Granule-associated serine proteases: granzymes might not just be killer proteases. Trends Immunol (2009) 1.00

Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol Ther (2005) 0.99

Immunosuppression routed via the kynurenine pathway: a biochemical and pathophysiologic approach. Adv Clin Chem (2008) 0.98

Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication. Mol Ther (2006) 0.98

Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl (2008) 0.98

Immunotherapy for neurological diseases. Clin Immunol (2008) 0.97

Protection against liver damage by cardiotrophin-1: a hepatocyte survival factor up-regulated in the regenerating liver in rats. Gastroenterology (2003) 0.97

Perforin rapidly induces plasma membrane phospholipid flip-flop. PLoS One (2011) 0.97

Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8(+) T cells. Eur J Immunol (2010) 0.96

Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice. Oncoimmunology (2012) 0.96

Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol Ther (2012) 0.96

Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development. Int J Cancer (2014) 0.95

Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12. Mol Oncol (2011) 0.95

Large cell carcinoma of the lung: an endangered species? Appl Immunohistochem Mol Morphol (2009) 0.95

Liver failure caused by herpes simplex virus thymidine kinase plus ganciclovir therapy is associated with mitochondrial dysfunction and mitochondrial DNA depletion. Hum Gene Ther (2003) 0.94

Adenovirus-mediated inhibition of SPARC attenuates liver fibrosis in rats. J Gene Med (2008) 0.94

Optimization of the Tet-on system to regulate interleukin 12 expression in the liver for the treatment of hepatic tumors. Cancer Res (2004) 0.94

Quiescent and activated mouse granulocytes do not express granzyme A and B or perforin: similarities or differences with human polymorphonuclear leukocytes? Blood (2005) 0.93